Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 4, 2013, Pages 909-916

  Foltz, Warren D ^a   Wu, Andy ^a   Chung, Peter ^a   Catton, Charles ^a   Bayley, Andrew ^a   Milosevic, Michael ^a   Bristow, Robert ^a   Warde, Padraig ^a   Simeonov, Anna ^a   Jaffray, David A ^a   Haider, Masoom A ^a   Ménard, Cynthia ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

ADC; prostate cancer; radiation therapy; T2; treatment response

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIFFUSION COEFFICIENT; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; GLEASON SCORE; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE;

AGED; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RISK; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875424738     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23885     Document Type: Article

References (49)

1. Kelloff GJ, Choyke P, Coffey DS, Prostate Cancer Imaging Working Group. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol 2009; 192: 1455-1470.
2. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011; 79: 1310-1317.
3. Martin JM, Bayley A, Bristow R, et al. Image guided dose escalated prostate radiotherapy: still room to improve. Radiat Oncol 2009; 4: 50.
4. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005; 102: 16759-16764. (Pubitemid 41688850)
5. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006; 8: 259-267.
6. Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA,. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol 2009; 48: 1034-1043.
7. Christensen E, Evans KR, Menard C, Pintilie M, Bristow RG,. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer Metastasis Rev 2008; 27: 372-285.
8. Menard C, Johann D, Lowenthal M, et al. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 2006; 66: 1844-1850. (Pubitemid 43259971)
9. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2008; 103: 883-888.
10. Langer D, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008; 249: 900-908.
11. Gibbs P, Liney GP, Pickles MD, Zelhof B, Rodrigues G, Turnbull LW,. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009; 44: 572-576.
12. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 425-430.
13. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, k(trans), v(e), and corresponding histologic features. Radiology 2010; 255: 485-494.
14. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2005; 241: 449-458.
15. Gibbs P, Tozer DJ, Liney GP, Turnbull LW,. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 2001; 46: 1054-1058. (Pubitemid 33104291)
16. Roebuck JR, Haker SJ, Mitsouras D, Rybicki FJ, Tempany CM, Mulkern RV,. Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination. Magn Reson Imaging 2009; 27: 497-502.
17. Storas TH, Gjesdal KI, Gadmar OB, Geitung JT, Klow NE,. Prostate magnetic resonance imaging: multiexponential T2 decay in prostate tissue. J Magn Reson Imaging 2008; 28: 1166-1172.
18. Liu W, Turkbey B, Senegas J, et al. Accelerated T2 mapping for characterization of prostate cancer. Magn Reson Med 2011; 65: 1400-1406.
19. Kershaw LE, Hutchinson CE, Buckley DL,. Benign prostatic hyperplasia: evaluation of T1, T2, and microvascular characteristics with T1-weighted dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009; 29: 641-648.
20. Foltz WD, Chopra S, Chung P, et al. Clinical prostate T2 quantification using magnetization-prepared spiral imaging. Magn Reson Med 2010; 64: 1155-1161.
21. Ray ME, Levy LB, Horwitz EM, et al. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 2006; 68: 1257-1262. (Pubitemid 44880342)
22. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007; 189: 323-328. (Pubitemid 47195916)
23. Mazaheri Y, Shukla-Dave A, Muellner A, et al. MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imaging 2011; 33: 258-274.
24. Harvey CJ, Blomley MJK, Dawson P, et al. Functional CT imaging of the acute hyperemic response to radiation therapy of the prostate gland: early experience. J Comput Assist Tomogr 2001; 25: 43-49. (Pubitemid 32099207)
25. Rouviere O, Valette O, Grivolat S, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings. Urology 2004; 63: 922-927. (Pubitemid 38596680)
26. Coakley FV, The HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233: 441-448. (Pubitemid 39423803)
27. Franiel T, Lüdemann L, Taupitz M, Böhmer D, Beyersdorff D,. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Radiother Oncol 2009; 93: 241-245.
28. Menard C, Smith IC, Somorjai RL, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 2001; 50: 317-323. (Pubitemid 32472261)
29. Ghilezan MJ, Jaffray DA, Siewerdsen JH, et al. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys 2005; 62: 406-417. (Pubitemid 40704457)
30. Padhani AR, Khoo VS, Suckling J, Husband JE, Leach MO, Dearnaley DP,. Evaluating the effect of rectal distension and rectal movement on prostate gland motion using cine MR. Int J Radiat Oncol Biol Phys 1999; 44: 525-533. (Pubitemid 29258426)
31. Wachter S, Gerstner N, Dorner D, et al. The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 91-100. (Pubitemid 34044109)
32. Nichol AM, Warde PR, Lockwood GA, et al. A cinematic magnetic resonance imaging study of milk of magnesia laxative and an antiflatulent diet to reduce intrafraction prostate motion. Int J Radiat Oncol Biol Phys 2010; 15: 1072-1078.
33. Lips IM, van Gils CH, Kotte AN, et al. A double-blind placebo-controlled randomized clinical trial with magnesium oxide to reduce intrafraction prostate motion for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 653-660.
34. Lips IM, Kotte AN, van Gils CH, et al. Influence of antiflatulent dietary advice on intrafraction motion for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81: e401-e406.
35. Kurland RJ,. Strategies and tactics in NMR imaging relaxation time measurements. I. Minimizing relaxation time errors due to image noise-the ideal case. Magn Reson Med 1985; 2: 136-158. (Pubitemid 15119031)
36. MacFall JR, Riederer SJ, Wang HZ,. An analysis of noise propagation in computed T2, pseudodensity, and synthetic spin-echo images. Med Phys 1986; 13: 285-292. (Pubitemid 16062258)
37. Kim SH, Lee JM, Hong SH, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009; 253: 116-125.
38. Liu Y, Bai R, Sun H, Liu H, Zhao X, Li Y,. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol 2009; 64: 1067-1074.
39. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009; 15: 986-994.
40. Issa B,. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 2002; 16: 196-200. (Pubitemid 34810058)
41. Kiliçkesmez O, Cimilli T, Inci E, et al. Diffusion-weighted MRI of urinary bladder and prostate cancers. Diagn Interv Radiol 2009; 15: 104-110.
42. Mulkern RV, Barnes AS, Haker SJ, et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006; 24: 563-568. (Pubitemid 43776563)
43. Kershaw LE, Logue JP, Hutchinson CE, Clarke NW, Buckley DL,. Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging. Radiother Oncol 2008; 88: 127-134.
44. Larocque MP, Syme A, Yahya A, Wachowicz K, Allalunis-Turner J, Fallone BG,. Temporal and dose dependence of T2 and ADC at 9.4 T in a mouse model following single fraction radiation therapy. Med Phys 2009; 36: 2948-2954.
45. Larocque MP, Syme A, Yahya A, Wachowicz K, Allalunis-Turner J, Fallone BG,. Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model. Phys Med Biol 2010; 55: 1381-1393.
46. Kroeker RM, Stewart CA, Bronskill MJ, Henkelman RM,. Continuous distributions of NMR relaxation times applied to tumors before and after therapy with X-rays and cyclophosphamide. Magn Reson Med 1988; 6: 24-36. (Pubitemid 18057205)
47. Liney GP, Turnbull LW, Lowry M, Turnbull LS, Knowles AJ, Horsman A,. In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging 1997; 15: 1177-1186. (Pubitemid 27516466)
48. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008; 249: 900-908.
49. Kjaer L, Thomsen C, Iversen P, Henriksen O,. In vivo estimation of relaxation processes in benign hyperplasia and carcinoma of the prostate gland by magnetic resonance imaging. Magn Reson Imaging 1987; 5: 23-30. (Pubitemid 17059055)